Abstracts tagged "joint damage and radiography"

Abstract Number: 1322 • 2015 ACR/ARHP Annual Meeting
How Can We Reduce the Time for Scoring Radiographic Joint Damage in Rheumatoid Arthritis? Initial Results with a New Computer-Based Documentation Tool
Alexander Langer¹, Joachim Böttcher², Diane M. Renz³, Alexander Pfeil⁴ and Hans-Eckhard Langer⁵, ¹Department of Computer Science, RWTH Aachen University, Aachen, Germany, ²Institute for Diagnostic and Interventional Radiology, SRH Waldklinikum, Gera, Germany, ³Institute for diagnostic and Interventional Radiology, Jena University Hospital - Friedrich Schiller University, Jena, Germany, ⁴Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University, Jena, Germany, ⁵RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany
Background/Purpose: Radiographic progression is a key outcome parameter in RA1. Manual scoring of joint damage based on the established scoring methods (e. g. Sharp Score)…
Abstract Number: 405 • 2014 ACR/ARHP Annual Meeting
14-3-3η: A Mechanistic Biomarker That Supports the Concept of “Uncoupling” of Inflammation and Joint Damage
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴, Kelly Young⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Rheumatoid Patient Foundation, Cocoa, FL, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose In RA, irreversible joint damage often begins within the first year of symptom onset. A compelling and growing body of data describing the "uncoupling"…
Abstract Number: 276 • 2013 ACR/ARHP Annual Meeting
Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
Clara Malattia¹, Nicolino Ruperto¹, Elena Palmisani¹, Silvia Pederzoli¹, Angela Pistorio¹, Hermine Brunner², Rubén J. Cuttica³, Inmaculada Calvo¹, Stella Maris Garay¹, Despina Eleftheriou¹, Carine Wouters¹, Jianmei Wang⁴, Clare Devlin⁴, Daniel J. Lovell², Alberto Martini⁵, Fabrizio De Benedetti⁶ and Angelo Ravelli⁵, ¹PRINTO, Genoa, Italy, ²PRCSG, Cincinnati, OH, ³Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy
Background/Purpose: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA).1,2 The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].